controlled substances; approval; use; research
SB1542 would create a new Arizona workers’ compensation benefit for firefighters and certified peace officers diagnosed with post-traumatic stress disorder (PTSD). If a qualifying claim is accepted and an independent medical examination finds midomafetamine to be a reasonable and necessary treatment under commission guidelines, the bill would allow coverage for one complete course of that treatment, prescribed by a psychiatrist. The bill also requires annual reporting to the Joint Legislative Budget Committee on the cost of this treatment.
The measure further directs the Arizona Department of Health Services to administer a $10 million general fund appropriation in fiscal year 2026-2027 for grants supporting clinical trials, applied research, and clinician training on midomafetamine for PTSD, especially for first responders and veterans. Eligible grantees would include certain clinical trial sponsors and Arizona public higher-education institutions, with requirements for product supply, regulatory authorization, and safety oversight. The appropriation would not lapse.
SB1542 also amends Arizona’s controlled substances laws to prepare for possible federal approval and rescheduling of midomafetamine and related 3,4-methylenedioxymethamphetamine (MDMA) products. It adds a new controlled-substances section stating that an FDA-approved and DEA-rescheduled MDMA product may be prescribed in Arizona, and it updates nomenclature provisions to include the new section. Several parts of the bill are conditional and would only take effect if federal approval and rescheduling occur by specified dates in 2027 or 2029.
The bill’s impact on state law would be significant but contingent: it would expand workers’ compensation coverage, create a state grant program, and modify Arizona’s controlled-substances framework to accommodate a federally approved psychedelic/MDMA-based PTSD treatment. It would also require the Industrial Commission to set reimbursement values and billing guidance if the treatment becomes available, and it would require the state board of pharmacy to notify legislative officials about whether the federal conditions were met.
The general sentiment appears cautiously favorable, at least in committee, as reflected by a 6-1 do-pass vote in the Senate Public Safety Committee. The bill’s focus on first responders, veterans, and PTSD treatment likely contributed to support. The main points of contention are implicit rather than documented in transcripts: the use of midomafetamine/MDMA in workers’ compensation and state-funded research, the size of the appropriation, and the bill’s reliance on future federal FDA/DEA action before any operative changes take effect.
SB1542 would amend Arizona workers’ compensation law and controlled-substances statutes, but most operative provisions are contingent on future federal approval. It would authorize workers’ compensation coverage for a PTSD treatment protocol using midomafetamine for firefighters and certified peace officers, require annual cost reporting, create a $10 million DHS grant program for research and clinician training, and add a new controlled-substances provision allowing an FDA-approved, DEA-rescheduled MDMA product to be prescribed in Arizona. It also directs the Industrial Commission and State Board of Pharmacy to take follow-up actions if the federal conditions are met.
The available voting history suggests the bill was received positively in the Senate Public Safety Committee, where it passed 6-1. No committee transcript is available, so there is no recorded debate to indicate broader support or opposition arguments. Based on the bill’s structure, the measure appears designed to appeal to public-safety and veterans’ interests while limiting immediate legal change through multiple federal-trigger conditions.
The likely areas of contention are the use of midomafetamine/MDMA as a PTSD treatment, the appropriateness of using state general fund dollars for clinical trials and training, and whether workers’ compensation should cover a novel treatment for a specific group of public-safety employees. Supporters would likely emphasize treatment access for firefighters, peace officers, and veterans, while opponents may question safety, efficacy, cost, and the wisdom of tying state law to future federal drug approvals. Because no transcript is provided, these points are inferred from the bill’s design rather than from recorded debate.